4-(4-甲氧基苯基)-2-甲基苯甲酸 | 104582-70-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(4-甲氧基苯基)-2-甲基苯甲酸
• 英文名称: 4'-methoxy-3-methyldiphenyl-4-carboxylic acid
• 英文别名: 4'-methoxy-3-methyl-biphenyl-4-carboxylic acid；4'-Methoxy-3-methyl-biphenyl-4-carbonsaeure；4'-Methoxy-3-methyl-[1,1'-biphenyl]-4-carboxylic Acid；4'-Methoxy-3-methyl[1,1'-biphenyl]-4-carboxylic acid；4-(4-methoxyphenyl)-2-methylbenzoic acid
• CAS: 104582-70-9
• 化学式: C₁₅H₁₄O₃
• 分子量: 242.274
• InChiKey: MACMBKKZFLACOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(4-甲氧基苯基)-2-甲基苯甲酸 在 吡啶 、 ammonium hydroxide 、 氯化亚砜 、 aluminum tri-bromide 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 10.0h， 生成 [4-(4-cyano-3-methylphenyl)phenyl] 4-pentylbenzoate
  参考文献：
  名称：

  Bezborodov, V. S.; Lapanik, V. I.; Petrovich, A. E., Journal of Organic Chemistry USSR (English Translation), 1986, vol. 22, # 7, p. 1338 - 1341

  摘要：

  DOI：
• 作为产物：
  描述：

  4-甲氧基苯基溴化镁 在 氢氧化钾 、 N-溴代丁二酰亚胺(NBS) 、 过氧化氢苯甲酰 作用下， 以 四氯化碳 、 乙醚 、 异丙醇 为溶剂， 反应 10.5h， 生成 4-(4-甲氧基苯基)-2-甲基苯甲酸
  参考文献：
  名称：

  Bezborodov, V. S.; Lapanik, V. I.; Petrovich, A. E., Journal of Organic Chemistry USSR (English Translation), 1986, vol. 22, # 7, p. 1338 - 1341

  摘要：

  DOI：

文献信息

• Biphenyl vasopressin agonists
  申请人：Wyeth

  公开号：US20030018024A1

  公开（公告）日：2003-01-23

  A compound of the formulae (I) or (II): 1 wherein: Y is a moiety selected from NR or —(CH 2 ) n ; wherein R is hydrogen or (C 1 -C 6 ) lower alkyl, and n is 1; 2 represents: (1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C 1 -C 6 ) lower alkyl, halogen, cyano, CF 3 , hydroxy, (C 1 -C 6 ) lower alkoxy, (C 1 -C 6 ) lower alkoxy carbonyl, carboxy, —CONH 2 , —CONH[(C 1 -C 6 ) lower alkyl], —CON[(C 1 -C 6 ) lower alkyl] 2 ; or (2) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C 1 -C 6 ) lower alkyl, halogen or (C 1 -C 6 ) lower alkoxy; 3 represents: (1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C 1 -C 6 ) lower alkyl, halogen, cyano, CF 3 , hydroxy, (C 1 -C 6 ) lower alkoxy, or (C 1 -C 6 ) lower alkoxy carbonyl, carboxy, —CONH 2 , —CONH[(C 1 -C 6 ) lower alkyl], —CON[(C 1 -C 6 ) lower alkyl] 2 ; or (2) a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C 1 -C 6 ) lower alkyl, (C 1 -C 6 ) lower alkoxy, or halogen; or (3) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C 1 -C 6 ) lower alkyl, halogen, or (C 1 -C 6 ) lower alkoxy; 4 represents a 5-membered aromatic (unsaturated) heterocyclic ring having one sulfur atom, optionally substituted by (C 1 -C 6 ) lower alkyl, halogen, or (C 1 -C 6 ) lower alkoxy; R 1 is a moiety of the formula 5 and R 2 , R 3 , R 7 , R 8 and R 9 are, independently, selected from a group consisting of hydrogen, (C 1 -C 3 ) lower alkyl, OCH 3 , halogen, CF 3 , —SCH 3 , OCF 3 , SCF 3 , or CN; or a pharmaceutically acceptable salt, or pro-drug form thereof.

  化合物的分子式（I）或（II）：其中：Y是从NR或—（CH2）n选择的基团；其中R是氢或（C1-C6）低碳烷基，n为1；2代表：（1）一个苯环，可选地取代一个或两个取代基，独立地选自包括氢，（C1-C6）低碳烷基，卤素，氰基，CF3，羟基，（C1-C6）低烷氧基，（C1-C6）低烷氧羰基，羧基，—CONH2，—CONH（C1-C6）低碳烷基，—CON（C1-C6）低碳烷基2的基团；或（2）含有一个氮原子的6成员芳香（不饱和）杂环环，可选地取代为（C1-C6）低碳烷基，卤素或（C1-C6）低烷氧基；3代表：（1）一个苯环，可选地取代一个或两个取代基，独立地选自包括氢，（C1-C6）低碳烷基，卤素，氰基，CF3，羟基，（C1-C6）低烷氧基，或（C1-C6）低烷氧羰基，羧基，—CONH2，—CONH（C1-C6）低碳烷基，—CON（C1-C6）低碳烷基2的基团；或（2）含有一个氮原子的5成员芳香（不饱和）杂环环，可选地取代为（C1-C6）低碳烷基，（C1-C6）低烷氧基，或卤素；或（3）含有一个氮原子的6成员芳香（不饱和）杂环环，可选地取代为（C1-C6）低碳烷基，卤素，或（C1-C6）低烷氧基；4代表含有一个硫原子的5成员芳香（不饱和）杂环环，可选地取代为（C1-C6）低碳烷基，卤素，或（C1-C6）低烷氧基；R1是公式5的基团，R2、R3、R7、R8和R9独立地选自氢，（C1-C3）低碳烷基，OCH3，卤素，CF3，—SCH3，OCF3，SCF3，或CN的基团；或其药学上可接受的盐或前药形式。
• Biphenyl Vasopressin Agonists
  申请人：FAILLI Amedeo A.

  公开号：US20090227565A1

  公开（公告）日：2009-09-10

  A compound of the formulae (I) or (II): wherein: Y is a moiety selected from NR or —(CH 2 ) n ; wherein R is hydrogen or (C 1 -C 6 ) lower alkyl, and n is 1; represents: (1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C 1 -C 6 ) lower alkyl, halogen, cyano, CF 3 , hydroxy, (C 1 -C 6 ) lower alkoxy, (C 1 -C 6 ) lower alkoxy carbonyl, carboxy, —CONH 2 , —CONH[(C 1 -C 6 ) lower alkyl], —CON[(C 1 -C 6 ) lower alkyl] 2 ; or (2) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C 1 -C 6 ) lower alkyl, halogen or (C 1 -C 6 ) lower alkoxy; represents: (1) a phenyl ring optionally substituted with one or two substituents selected, independently, from the group comprising hydrogen, (C 1 -C 6 ) lower alkyl, halogen, cyano, CF 3 , hydroxy, (C 1 -C 6 ) lower alkoxy, or (C 1 -C 6 ) lower alkoxy carbonyl, carboxy, —CONH 2 , —CONH[(C 1 -C 6 ) lower alkyl], —CON[(C 1 -C 6 ) lower alkyl] 2 ; or (2) a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C 1 -C 6 ) lower alkyl, (C 1 -C 6 ) lower alkoxy, or halogen; or (3) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom, optionally substituted by (C 1 -C 6 ) lower alkyl, halogen, or (C 1 -C 6 ) lower alkoxy; represents a 5-membered aromatic (unsaturated) heterocyclic ring having one sulfur atom, optionally substituted by (C 1 -C 6 ) lower alkyl, halogen, or (C 1 -C 6 ) lower alkoxy; R 1 is a moiety of the formula and R 2 , R 3 , R 7 , R 8 and R 9 are, independently, selected from a group consisting of hydrogen, (C 1 -C 3 ) lower alkyl, OCH 3 , halogen, CF 3 , —SCH 3 , OCF 3 , SCF 3 , or CN; or a pharmaceutically acceptable salt, or pro-drug form thereof.

  化合物的结构式为(I)或(II)，其中：Y是从NR或—(CH2)n选择的基团；其中R是氢或(C1-C6)低级烷基，n为1；表示：(1)苯环，可选地取代一个或两个取代基，独立地从羟基，(C1-C6)低级烷基，卤素，氰基，CF3，(C1-C6)低级烷氧基，(C1-C6)低级烷氧基羰基，羧基，—CONH2，—CONH[(C1-C6)低级烷基]，—CON[(C1-C6)低级烷基]2中选择；或(2)具有一个氮原子的6元芳香(不饱和)杂环，可选地取代(C1-C6)低级烷基，卤素或(C1-C6)低级烷氧基；表示：(1)苯环，可选地取代一个或两个取代基，独立地从羟基，(C1-C6)低级烷基，卤素，氰基，CF3，(C1-C6)低级烷氧基，或(C1-C6)低级烷氧基羰基，羧基，—CONH2，—CONH[(C1-C6)低级烷基]，—CON[(C1-C6)低级烷基]2中选择；或(2)具有一个氮原子的5元芳香(不饱和)杂环，可选地取代(C1-C6)低级烷基，(C1-C6)低级烷氧基或卤素；或(3)具有一个氮原子的6元芳香(不饱和)杂环，可选地取代(C1-C6)低级烷基，卤素或(C1-C6)低级烷氧基；表示具有一个硫原子的5元芳香(不饱和)杂环，可选地取代(C1-C6)低级烷基，卤素或(C1-C6)低级烷氧基；R1是公式的基团，R2、R3、R7、R8和R9独立地选择自氢，(C1-C3)低级烷基，OCH3，卤素，CF3，—SCH3，OCF3，SCF3或CN的群体；或其药学上可接受的盐或前药形式。
• A switch to vinylogous reactivity of vinyl diazo esters for the C–H allylation of benzamides by merging cobalt and photoredox catalysis
  作者：Nandkishor Prakash Khot、Nitish Kumar Deo、Manmohan Kapur

  DOI：10.1039/d2cc05332b

  日期：——

  Herein, a de novo vinylogous reactivity of vinyl diazo esters in the C–H bond allylation of benzamides has been developed by coalescing cobalt and photoredox catalysis via C–H activation/allyl carbene migratory insertion. A close relationship between the high valent cobalt catalyst and the photocatalyst has been found to be crucial for this reactivity. The reaction uses oxygen as the sole oxidant and

  在此，通过C-H 活化/烯丙基卡宾迁移插入聚结钴和光氧化还原催化，开发了乙烯基重氮酯在苯甲酰胺的 C-H 键烯丙基化中的从头插烯反应性。已发现高价钴催化剂和光催化剂之间的密切关系对于这种反应性至关重要。该反应使用氧气作为唯一的氧化剂，并产生良性氮作为唯一的副产品。对于乙烯基重氮酯和苯甲酰胺，该反应显示出良好的底物范围。该协议的实用性通过几个生物活性分子的后期功能化得到证明。
• A three component 1,3-difunctionalization of vinyl diazo esters enabled by a cobalt catalyzed C–H activation/carbene migratory insertion
  作者：Nandkishor Prakash Khot、Prajyot Jayadev Nagtilak、Nitish Kumar Deo、Manmohan Kapur

  DOI：10.1039/d3cc00295k

  日期：——

  We report herein, a modular, regioselective 1,3-oxyarylation of vinyl diazo esters via a Co-catalyzed C–H activation/carbene migratory insertion cascade. The transformation involves the formation of C–C and C–O bonds in a one-pot fashion and displays a broad substrate scope with respect to both, vinyl diazo esters as well as benzamides. The coupled products were subjected to hydrogenation to access

  我们在此报告了通过共催化的 C-H 活化/卡宾迁移插入级联对乙烯基重氮酯进行模块化、区域选择性 1,3-氧芳基化。这种转化涉及以一锅法形成 C-C 和 C-O 键，并显示出与乙烯基重氮酯和苯甲酰胺有关的广泛底物范围。对偶联产物进行氢化以获得难以捉摸的烯丙醇支架。机理研究揭示了对转化模式的有趣见解，包括 C-H 活化、重氮化合物的卡宾迁移插入以及随后的自由基加成作为转化的关键步骤。
• Potential antifertility agents. 4. Biological properties of diastereoisomeric 4-aryl-2-methylcyclohexanecarboxylic acids and related compounds
  作者：R. R. Crenshaw、George M. Luke、Thomas A. Jenks、Richard A. Partyka、Gabriel Bialy、Max E. Bierwagen

  DOI：10.1021/jm00265a015

  日期：1973.7